Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27627024 | 0.80 | — | — | |
| SCHEMBL9229201 | 0.77 | NPC1 (0.31) | — | |
| SCHEMBL6010037 | 0.77 | — | — | |
| SCHEMBL19432853 | 0.77 | — | — | |
| SCHEMBL1132231 | 0.77 | — | — | |
| SCHEMBL572461 | 0.77 | — | — | |
| SCHEMBL6010020 | 0.77 | — | — | |
| SCHEMBL8976008 | 0.76 | CHRNB2 (0.35) | TDP1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL10349045 | 0.75 | TDP1 (0.37) | TDP1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL11326837 | 0.73 | GABRR1 (0.39) | TDP1CHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | claimed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | claimed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | claimed |
| US-7132419-B2 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2006-11-07 | — | — | US | disclosed |
| US-20050143383-A1 | Pharmaceutical compounds | XENOVA LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | XENOVA LIMITED (GB) | 2003-07-24 | — | — | US | disclosed |
| EP-1240148-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | Xenova Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001046157-A1 | BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II | XENOVA LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-0492464-A2 | Reactive feed stream to replace inert blowing agent feed stream in a polyurethane foam process | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 1992-07-01 | — | — | EP | disclosed |
| US-5084486-A | Polymerization and blowing followed by molding | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1992-01-28 | — | — | US | disclosed |
| US-4536599-A | HYDROLYZING THE NITRILE DERIVATIVE TO THE AMIDE USING AN ORGANIC QUATERNARY AMINE SALT CATALYST; EFFICIENCY | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-08-20 | — | — | US | disclosed |
| EP-0040896-B1 | SYNTHESIS OF AMIDES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-04-25 | — | — | EP | disclosed |
| EP-0040896-A2 | Synthesis of amides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1981-12-02 | — | — | EP | disclosed |
| EP-0008532-A1 | Synthesis of amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1980-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143383-A1 | Pharmaceutical compounds | CHRNA10, OPRM1, SCN10A | TDP1 4765/4885CHRNB2 160/4885CHRNB4 225/4885 |
| US-20030139409-A1 | Benzo[A] [phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase I and II | TOP1, TOP2A, TOP2B | TDP1 46/4885CHRNB2 586/4885CHRNB4 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.